The last bull run started when the 2wk phase 1b trial interim results were reported on Oct. 27. As you may recall, the number of patients treated was small, but the result of 2 wk treatment with 950+IFN minus RBV followed by 24 wks of IFN+RBV was impressive; 8 out of 8 had no detectable HCV RNA at the end of this course and 5 out of 6 who had chosen not to continue to take IFN+RBV beyond 24 wks were HCV negative at the 12 wk point after treatment termination.
PROVE 2 has an arm of 950+IFN w/o RBV followed by IFN+RBV. This time the statistics will be better and the main course lasts 12 wks instead of 2 wks. The interim result for this arm should be just as good as the PROVE 1 interim result, but the side effects should be less than those of PROVE 1. This reasoning is based on the observation that severe rash and other SE are result of additivity of RBV SE and 950 SE. When these drugs are not given at the same time, the sensitive patient number should be smaller. This would be very positive, because less SEs mean 950 can reach a greater fraction of the pool of HCV patients.
Does any one remember when PROVE 1 and PROVE 2 trials began? I want to estimate approximate date of PROVE 2 interim report.